Covance, acquired by LabCorp for about $6 billion earlier this year, has picked former head of R&D Deborah Keller to take the reins as CEO Joseph Herring retires.
Covance, recently acquired by testing giant LabCorp, has opened a new, expanded clinical research unit in Texas, pairing space for trials alongside a planned patient-service center operated by its parent company.
CROs Icon and Covance signed a pair of separate partnerships in the world of cancer diagnostics, each betting that new technologies in oncology testing will increase global demand.
Covance, now a division of LabCorp, has signed a two-year partnership with the Society for Clinical Research Sites, joining a growing list of CROs working to improve communication between sponsors and investigators.
LabCorp, now the owner of CRO giant Covance, partnered up with Japan's Sysmex to bring in some new technology it believes will make its subsidiary more competitive in the market for oncology clinical trials.
Sihuan Pharmaceutical said it has successfully enrolled the first patient in the United States for its Phase I clinical trial of Pirotinib developed by Shandong XuanZhu Pharma, a wholly owned subsidiary, working with Covance on preparation and initiation.
Hong Kong-listed Sihuan Pharmaceutical said it has joined hands with U.S.-based Covance to develop a drug pipeline aimed at China and U.S. approvals.
LabCorp closed its $5.7 billion takeover of Covance this week and immediately began talking up the potential for its testing data to turbocharge the CRO's clinical trial business.
One of the world's largest CROs is no longer an independent entity as Covance has folded into testing giant LabCorp, closing a $6 billion deal and altering the industry landscape.
Covance posted a roughly 2% increase in sales last quarter, weeks before merging with LabCorp in a $6 billion deal that management says will help the CRO accelerate its growth.